What we know about COVID-19 and its treatment

Abstract

Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) which is the human coronavirus and a member of the Coronaviridae family leads to fatal pneumonia cases. Severe acute respiratory syndrome corona virus 2 attaches to the cells in the human body through binding to the angiotensin converting enzyme 2 (ACE2) receptor with the spike (S) protein. Firstly, SARS-CoV-2 arised in China in late 2019 and was reported to the World Health Organization (WHO). The World Health Organization named the disease caused by this virus as corona virus disease (COVID)-19. SARS-CoV-2 which has human-to-human transmission through droplets, direct contact and aerosol routes have affected more than 10 million people and caused more than 500 thousand deaths. Clinical symptoms of COVID19 are fever, dry cough, sore throat, respiratory distress, lung damage, and diarrhea. In severe cases, mechanical ventilation is required and multiple organ damage is encountered. COVID-19 is diagnosed with real-time polymerase chain reaction (PCR) technique which is applied to saliva and swab samples taken from the nose or nasal cavity. Lung damage is detected by computerized tomography (CT). COVID-19 develops more severely in patients with comorbidities such as hypertension, diabetes and cancer. While vaccine and drug development studies are continuing all over the world, available antiviral drugs such as umifenovir, remdesivir, favipiravir are also tested against SARSCoV-2. Moreover, the plasma donated from the recovered patients are tested for COVID-19 treatment. Additionally, treating the inflammatory conditions developing due to COVID-19 and applying antimicrobial drugs against coinfections are among the current approaches.

Keywords

• : SARS-CoV-2
• COVID-19
• COVID-19 comorbidities
• COVID-19 treatment

References

1. [1] WHO Summary of probably SARS cases with onset of illness from 1 November 2002 to 31 July 2003. http://www.who.int/csr/sars/country/table2004_04_21/en/ (accessed June 26, 2020).
2. [2] WHO SARS (Severe Acute Respiratory Syndrome). https://www.who.int/ith/diseases/sars/en/ (accessed July 10, 2020).
3. [3] WHO MERS Monthly Summary, November 2019. https://www.who.int/emergencies/mers-cov/en/ (accessed June 26, 2020).
4. [4] WHO Coronavirus disease (COVID-19) pandemic situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed June 26, 2020).
5. [5] WHO Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novelcoronavirus2019?gclid=Cj0KCQjwoub3BRC6ARIsABGhnybkbwRUe6DkDxC87G3rgSN5BqIaUVQK7ohEvvpH0WiIy3NjUiNtd QgaApiuEALw_wcB (accessed July 01, 2020).
6. [6] Singh A, Shaikh A, Singh R, Singh AK. COVID-19: From bench to bed side. Diabetes Metab Syndr. 2020; 14: 277-281. [CrossRef]
7. [7] Lukassen S, Chua RL, Trefzer T, Khan NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Elis R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020; 39(10): e105114. [CrossRef]
8. [8] Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and Diabetes: Knowledge in Progress. Diabetes Res Clin Pract. 2020; 162: 108142. [CrossRef]

9. [9] Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis. EXCLI J. 2020; 19: 410-417. [CrossRef]
10. [10] Hoffmann M, Keline-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlman S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271-280. [CrossRef]
11. [11] Brojakowska A, Narula J, Shimony R, Bander J. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. J Am Coll Cardiol. 2020; 75(24): 3085-3095. [CrossRef]
12. [12] Kreutz R, El_hady Algharably EA, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, Persu A, Prejibsz A, Riemer TG, Wang JG, Burnier M. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020; 0: 1-12. [CrossRef]
13. [13] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesier D. Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein. Cell. 2020; 181(2): 281-292.e6. [CrossRef]
14. [14] Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46: 586–590. [CrossRef]
15. [15] Haköksüz M, Kılıç S, Saraç F. Coronaviruses and SARS-COV-2. Turkish J Med Sci. 2020; 50: 459-456. [CrossRef]
16. [16] Shi J, Wen Z, Zhong G, Yang H, Wang C. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS coronavirus-2. Science. 2020; 368(6494): 1016-1020. [CrossRef]
17. [17] WHO Transmission of SARS-CoV-2: implications for infection prevention precautions. https://www.who.int/newsroom/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions (accessed date July 17,2020)
18. [18] Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20(4): 425-34. [CrossRef]
19. [19] Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan COVID-19. bioRxiv. 2020; 01.26.919985. [CrossRef]
20. [20] Acharya A, Kevadiya BD, Gendelman HE, Byrareddy SN. SARS-CoV-2 Infection Leads to Neurological Dysfunction. J Neuroimmune Pharm. 2020; 15: 167–173. [CrossRef]
21. [21] Li H, Xue Q, Xu X. Involvement of the Nervous System in SARS-CoV-2 Infection. Neurotox Res. 2020; 38(1): 1-7. [CrossRef]
22. [22] Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in downtown Los Angeles, early April 2020. Brain Behav Immun. 2020; 87: 33. [CrossRef]
23. [23] Singal CMS, Jaiswal P, Seth P. SARS-CoV-2 more than a respiratory virus: Its potential role in neuropathogenesis. ACS Chem Neurosci. 2020; 11(13): 1887-1899. [CrossRef]
24. [24] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infection. 2020; 80: 607- 13. [CrossRef]
25. [25] Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, Deng Y, Wei S. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Respir Dis. 2020; 43(0): E005. [CrossRef]
26. [26] Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, Choolani M, Mattar C, Su LL. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020; 222(6): 521-531. [CrossRef]
27. [27] Chakrabotry C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020; 24(7): 4016-4026. [CrossRef]
28. [28] Song F, Shi n, Shan F, Zhang Z, Shen J, Lu H, Ling Y, Jiang Y, Shi Y. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020; 295: 210-217. [CrossRef]
29. [29] Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020; 126(12): 1671-1681. [CrossRef]
30. [30] Rossi GP, Sanga V, Barton M. Potential Harmful Effects of Discontinuing ACE-Inhibitors and ARBs in Covid-19 Patients. Elife. 2020; 9: e57278. [CrossRef]
31. [31] Cure E, Cure MC. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr. 2020; 14(4): 349–350. [CrossRef]
32. [32] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Current Cardiology Reports. 2020; 22(5): 31. [CrossRef]
33. [33] Kai H, Kai M. Interactions of Coronaviruses With ACE2, Angiotensin II, and RAS Inhibitors-Lessons From Available Evidence and Insights Into COVID-19. Hypertens Res. 2020; 43(7): 648-654. [CrossRef]
34. [34] Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8): 875-879. [CrossRef]
35. [35] Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112-116. [CrossRef]
36. [36] Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. SAVE Proc. 2018; 31(4): 419e23. [CrossRef]
37. [37] Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020; 14: 283-287. [CrossRef]
38. [38] ESC Council on Hypertension Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. https://www.escardio.org/Councils/Council-on-Hypertension- (CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (accesed June 10, 2020).
39. [39] European Society of Hypertension, Statement of the European Society of Hypertension (ESH) on hypertension, renin angiotensin system blockers and COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ (accessed June 10, 2020).
40. [40] Statement from the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid19-should-continue-treatment-unlessotherwise-advised-by-their-physician (accessed June 10, 2020).
41. [41] Ma RCW, Holt RIG. COVID-19 and diabetes. Diabet Med. 2020; 00: 1–3. [CrossRef]
42. [42] Kohio Hinissan P, Adamson Amy L. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013; 444(1-2): 301–309. [CrossRef]
43. [43] Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int J Mol Sci. 2017; 18(3): 563. [CrossRef]
44. [44] Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalance, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020; 14: 303-310. [CrossRef]
45. [45] Fernandez C, Rysa J, Almgren P, Nilsson J, Engström G, Orho-Melander M, Ruskoaho H, Melander O. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018; 284(4): 377-87. [CrossRef]
46. [46] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020; 323(13): 1239-1242. [CrossRef],
47. [47] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS and for the China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-1720. [CrossRef]
48. [48] Brufsky A. Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic. J Med Virol. 2020; 92: 770–775. [CrossRef]
49. [49] Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020; 159(1): 367-370. [CrossRef]
50. [50] Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020; 41(3): bnaa011. [CrossRef]
51. [51] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223): 473-475. [CrossRef]
52. [52] Zhou J, Tan J. Diabetes patients with COVID-19 need better Blood Glucose Management in Wuhan, China. Metabolism. 2020; 107: 154216. [CrossRef]
53. [53] Ahsan W, JAved S, Al Bratty M, Alhazmi HA, Najmi A. Treatment of SARS-CoV-2: How far have we reached? Drug Discov Ther. 2020; 14(2): 67-72. [CrossRef]
54. [54] Yu L, Yuan K, Phuong HT, Park BM, Kim SH. Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor. Peptides. 2016; 86: 33–41. [CrossRef]
55. [55] Battle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020; 134 (5): 543–545. [CrossRef]
56. [56] Lei C, Fu W, Qian K, Li T, Zhang S, Ding M, Hu S. Potent neutralization of 2019 novel coronavirus by recombinant ace2-ig. BioRxiv. 2020. [CrossRef]
57. [57] Zhang F, Liu J, Li SF, Song JX, Ren JY, Chen H. Angiotensin-(1-7): new perspectives in atherosclerosis treatment. J Geriatr Cardiol. 2015; 12: 676-682. [CrossRef]
58. [58] Padda RS, Shi Y, Lo CS, Zhang SL, Chan J. Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes? J Diabetes Metab. 2015; 6(10): 10.4172/2155-6156.1000615. [CrossRef]
59. [59] Perio C, Moncada S. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection? Circulation. 2020; 141: 1665–1666. [CrossRef]
60. [60] Pal R, Phadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020; 163: 108146. [CrossRef]
61. [61] Gendrot M, Javelle E, Clerc A, Savini H, Pradines B. Chloroquine as a prophylactic agent against COVID-19? Int J Antimicrob Agents. 2020; 55(6): 105980. [CrossRef]
62. [62] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-71. [CrossRef]
63. [63] Shiratori H, Feinweber C, Luckhardt S, Wallner N, Geisslinger G, Weigert A, Parnham MJ. An in vitro test system for compounds that modulate human inflammatory macrophage polarization. Eur J Pharmacol. 2018; 833: 328-338. [CrossRef]
64. [64] Rekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B, Solomon DH. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010; 62(12): 3569-3573. [CrossRef]
65. [65] Gao J, Tian Z,Yang X.Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BiosciTrends. 2020; 14(1): 72-73. [CrossRef]
66. [66] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giodanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 105949. [CrossRef]
67. [67] Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020. [CrossRef]
68. [68] Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15): 732-739. [CrossRef]
69. [69] Colson P, Rolain JM,Lagier JC,Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020; 55(4): 105932. [CrossRef]
70. [70] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review. JAMA. 2020; 323(18): 1824-1836. [CrossRef]
71. [71] Kalil AC. Treating COVID-19—off-labe ldrug use, compassionate use,and randomized clinical trials during pandemics. JAMA. 2020; 323(19): 1897-1898. [CrossRef]
72. [72] Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated Approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020; 64: e00483-20. [CrossRef]
73. [73] National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Chin Med J. 2020; 133: 1087–1095. [CrossRef]
74. [74] WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavirritonavir-treatment-arms-for-covid-19 (accessed June 27, 2020).
75. [75] Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad SciUSA. 2017; 114(2): 206-214. [CrossRef]
76. [76] Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15): 769-777. [CrossRef]
77. [77] Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley L, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RSN, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, PAlmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie Di Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC. Late Ebola virus relapse causing meningo encephalitis:a case report. Lancet. 2016; 388(10043): 498-503. [CrossRef]
78. [78] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271. [CrossRef]
79. [79] Cai Q, Yang M, Liu D. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering. 2020. [CrossRef]
80. [80] Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, Hu M, Fang M, Gao Y. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020; 5: 18. [CrossRef]
81. [81] Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020; 53: 436-443. [CrossRef]
82. [82] Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020; 20: 398-400. [CrossRef]
83. [83] Zeiser R. Immune modulatory effects of statins. Immunology. 2018; 154: 69–75. [CrossRef]
84. [84] Castiglione V, Chiriaco M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020; 6(4): 258-259. [CrossRef],
85. [85] Chansrichavala P, Chantharaksri U, Sritara P, Chaiyaroj SC. Atorvastatin attenuates TLR-4mediated NF-kappa B activation in a MyD88-dependent pathway. Asian Pac J Allergy Immunol. 2009; 27: 49-57.
86. [86] Totura AL, Whitmore A, Agnlhram S, Schäfer A, Katze MG, Heise MT, Baric RS. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015; 6(3): e00638-15. [CrossRef]
87. [87] Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020; 11(2): e00398-20. [CrossRef]
88. [88] Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dosedependent effects of statins. Chest. 2007; 131(4): 1006-1012. [CrossRef]
89. [89] Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; 40(5): 998-1004. [CrossRef]
90. [90] Massacheusetts General Hospital Rationale for Consideration of Statins for COVID-19 Patients. https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/covid-19_domID_statin.pdf (accessed July, 02 2020)
91. [91] WHO Novel coronavirus technical guidance: patient management. https://www.who.int/emergencies/diseases/novel-coronavirus2019/technical-guidance/patient-management (accessed February 20, 2020).